NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to ...

A股市场近期情绪高涨，上证指数成功站上3800点，创业板的表现也不遑多让，创业板指数近3个月涨 幅超30%，创下近三年新高。 创业板行情汹涌之下，创业板ETF（159915）持续受资金关注，截至8月25日，该产品本月以来规模增 长约150亿元，最新规模已超1000亿元。 创业板的定位是服务成长型创新创业企业，板块内高新技术企业占比超九成，战略性新兴产业占比近 70%。新兴产业今年发展迅猛，人形机器人概念爆发、创新药加速出海、低空经济获政策大力支持，支 持新兴产业发展的创业板也受到了市场关注。 · 16万亿市值背后：创业板的"创新"底色 创业板于2009年开板，至今已走过16年。截至8月25日，创业板共有上市公司1380余家，总市值超过16 万亿元。 目前，创业板既有市值不足百亿的中小企业，也有市值在千亿甚至是万亿元以上"大象也能起舞"的行业 龙头。 图：创业板企业市值分布 数据来源：Wind，市值采用"总市值1"指标，数据截止到：2025/8/25。 在创业板的助推下，近年来，我国众多创新创业企业在全球产业竞争中崭露头角，创业板企业取得了令 人瞩目的成果：有的企业动力电池全球市占率近40%，连续多年排名第一； ...

Summary of Terumo's Acquisition of Organox Company Overview - **Company Involved**: Terumo Corporation (TRUM.Y) - **Acquisition Target**: Organox, headquartered in Oxford, UK - **Acquisition Date**: Agreement signed on August 23, 2025 - **Acquisition Value**: $1,500,000,000 for 100% of Organox's outstanding shares [4][5][6] Core Points and Arguments - **Strategic Importance**: The acquisition marks Terumo's entry into the organ transplantation market, specifically focusing on organ preservation technology [4][8][10] - **Market Demand**: Global organ transplants exceed 150,000 annually, with a waiting list of approximately 470,000 patients, indicating a significant unmet need for transplant organs [10][11] - **Organox's Technology**: Organox's METRA device utilizes normothermic machine perfusion (NMP) to preserve livers, allowing for longer preservation times (up to 12 hours in the US and 24 hours in Europe) compared to traditional methods [14][15] - **Growth Potential**: Organox's sales revenue was $71,000,000 in 2024, with projections to reach JPY 100,000,000,000 (approximately $670 million) within the next decade [7][18] - **Synergies with Terumo**: The acquisition is expected to create synergies with Terumo's existing product portfolio, enhancing overall corporate value and expanding into new growth domains [8][20][22] Financial Implications - **Positive Impact on Earnings**: The acquisition is anticipated to positively affect adjusted operating profit and earnings per share starting next fiscal year [19][20] - **Growth Model**: Organox has achieved positive adjusted EBITDA just one year after its US launch, which is rare for startups, indicating a strong business model [18][20] Market Dynamics - **Challenges in Organ Transplantation**: The market faces challenges such as a low utilization rate of donated livers and a shortage of donors, particularly from donation after circulatory death (DCD) [12][13] - **Technological Advantage**: Organox's NMP technology addresses these challenges by improving the preservation and assessment of organ viability, potentially increasing the number of transplantable organs [14][15][16] Future Outlook - **Expansion Plans**: Terumo plans to expand beyond liver transplantation into kidney transplants, targeting a launch around 2030 [16][17] - **Long-term Growth Strategy**: The acquisition is part of Terumo's broader strategy to achieve significant growth and address the critical shortage of transplant organs [8][22] Additional Insights - **Cultural Fit and Synergy**: The acquisition aligns with Terumo's strategic direction, emphasizing the importance of groundbreaking technology and cultural compatibility [24][25] - **Regulatory Approvals**: Organox's METRA device has received CE marking and FDA approval, facilitating its market entry and growth [6][10] This summary encapsulates the key points from the conference call regarding Terumo's acquisition of Organox, highlighting the strategic importance, market dynamics, financial implications, and future growth potential.

Acquisition of OrganOx ~Expanding transplant opportunities for waiting patients globally and contributing to the development of transplant medicine~ Terumo Corporation Chief Executive Officer Hikaru Samejima August 27, 2025 Acquisition Overview | Target Company | OrganOx Limited | | --- | --- | | Acquisition Price | $1.5B（cash free / debt free basis） | | Transaction | Acquisition of 100% of OrganOx's outstanding shares in cash consideration | | Structure | | | Signing Date | August 23, 2025 | | | *Closing i ...

Core Insights - Verily, Alphabet's life sciences company, has announced staff cuts and the discontinuation of its devices program as part of a strategic refocus towards AI and infrastructure development [1][2][5] - The decision to wind down the devices program is attributed to the inability to support the necessary investment for long-term growth and scaling [3][10] Company Strategy - Verily has been on a journey to streamline operations and cut costs since 2023, focusing on precision health, data, and AI strategies [2][5] - The company aims to become a fully independent entity, gradually detaching from the technology and services shared with Google [6] Workforce Impact - The exact number of employees affected by the cuts has not been disclosed, but the company has made workforce reductions across various departments [4][7] - Employee benefits have been reduced, and salary bands have been adjusted to align with the healthcare industry rather than the technology sector [7] Devices Program Legacy - The devices program was responsible for several innovative projects, including a clinical study watch and a partnership with Dexcom for a wearable glucose sensor [3][9] - The company acknowledges the significant contributions of employees in the devices organization, highlighting their dedication and impact on healthcare technology [4][11]

MINNEAPOLIS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its Chief Financial Officer, Rick Buchholz, will be stepping down from his current position with the Company, effective December 31, 2025, in order to pursue other professional opportunities. Buchholz will remain employed wit ...

REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that management will present at the following investor conferences: Wells Fargo Healthcare ConferenceFormat: Fireside Chat and 1x1 meetingsDate: Thursday, September 4 at 1:30 pm PT/ 4:30 pm ETLocation: Boston, MAWebcast Link: Click here Lake Street Best Ideas Growth (BIG9) ConferenceFormat: 1x1 meetingsDate ...

ORLANDO, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in innovative medical devices for Magnetic Resonance Imaging (“MRI”) compatible patient monitoring and infusion systems, today announced that it will participate in the Wells Fargo 2025 Healthcare Conference, held September 3-5, 2025, in Boston, Massachusetts. Roger Susi, President and CEO, and Jack Glenn, CFO, will host 1x1 investor meetings at the 2025 Wells Fargo Healthcare Conference on September 4, 2025, in B ...

SANTA CLARA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Tuesday, September 9, 2025, at 4:00 a.m. Pacific Time/ 07:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at thi ...

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cearvol today announced the launch of Wave Lite, a next-generation hearing aid designed to blend clarity, comfort, and style. Powered by Cearvol AI 2.0, Wave Lite helps users reconnect with life’s important sounds—whether in daily conversations, at home with family, or on the go. Shaped like a modern earbud and paired with a fabric-wrapped charging case, Wave Lite delivers both powerful support and emotional comfort. Recognized as one of the best OTC hearing aids ...